The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Even in those virions that share basic icosahedral and helical capsid symmetry, remarkable complexity has evolved to promote viral propagation ... cone capsids of HIV-1, the multi-membrane ...

The FDA granted priority review, with a decision expected by 19 June 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

To become infectious, HIV has to undergo a maturation process. This involves the HIV-1 protease (a viral enzyme), that cuts up Gag into six smaller proteins including the capsid protein and the matrix ...

HIV medications can help lower your viral load, fight infections ... blocking the protein shell of the HIV-1 virus, known as the capsid. Lenacapavir(Sunlenca) is initially given as oral tablets ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

CCR5 inhibitors, with one now on the market, suggest it may be a good defense Stem cells and gene therapy: Researchers take a second look at using stem cells to treat HIV Solving the viral spike: Can ...

Home-based HIV counseling and relationship building improved HIV testing, diagnoses and viral suppression among pregnant couples during a trial in Kenya, researchers reported. Two more people have ...

More than 98% of participants in both groups had what's known as "viral suppression," or undetectable levels of HIV, after 48 weeks. It is the largest and longest such comparison. The paper ...